# RGS2

## Overview
RGS2, or Regulator of G Protein Signaling 2, is a gene that encodes a protein involved in the modulation of G protein-coupled receptor (GPCR) signaling pathways. The RGS2 protein functions as a GTPase-activating protein (GAP), primarily targeting Gα subunits, such as Gαq, to accelerate the hydrolysis of GTP to GDP, thereby terminating GPCR signaling. This regulatory mechanism is crucial for maintaining physiological homeostasis, particularly in the cardiovascular system, where RGS2 plays a significant role in blood pressure regulation by modulating vasoconstrictor signaling (Heximer2003Hypertension; McNabb2020Emerging). The protein is characterized by a conserved RGS domain, which is essential for its interaction with Gα subunits, and is subject to post-translational modifications and alternative splicing, which can influence its function and localization (Tesmer2009Chapter; Ross2000GTPaseActivating). Beyond cardiovascular regulation, RGS2 is implicated in various physiological processes, including neurotransmitter modulation in the central nervous system and inflammatory response regulation, highlighting its diverse functional roles (McNabb2020Emerging).

## Structure
RGS2 is a protein characterized by a conserved RGS domain, approximately 120-130 amino acids in length, which is crucial for its function as a GTPase-activating protein (GAP) (Tesmer2009Chapter; Ross2000GTPaseActivating). This domain is globular and mostly helical, consisting of a four-helix bundle and a second subdomain, allowing it to bind directly to activated Gα subunits and accelerate GTP hydrolysis (Ross2000GTPaseActivating). The RGS domain interacts with Gα subunits over a discontinuous interface, including interhelix loops that contact the switch regions in the GTP-binding domain of Gα (Ross2000GTPaseActivating).

RGS2 is a relatively small protein, typically 20-30 kDa, with a conserved RGS domain flanked by short amino and carboxy termini (AbramowNewerly2006RGS). The amino terminal domain is implicated in GPCR binding, and deletion of this region reduces its ability to inhibit receptor-mediated signals (AbramowNewerly2006RGS). Specific amino acid residues, such as Cys 106, Asn 184, and Glu 191, play a role in its selectivity for Gα subunits, with mutations at these sites affecting binding affinity and specificity (Kimple2009Structural).

RGS2 may undergo post-translational modifications like phosphorylation, and it has several splice variant isoforms, which can affect its function and localization (Tesmer2009Chapter). These structural features and modifications are crucial for its role in modulating G protein-coupled receptor signaling pathways.

## Function
The RGS2 gene encodes a protein that plays a critical role in modulating G protein-coupled receptor (GPCR) signaling pathways by acting as a GTPase-activating protein (GAP) for Gα subunits, particularly Gαq. This function is crucial for the rapid termination of GPCR signaling, which is essential for maintaining normal physiological processes (Heximer2003Hypertension; McNabb2020Emerging). RGS2 is highly expressed in tissues involved in blood pressure regulation, such as the nervous system, kidney, and vascular smooth muscle cells, where it helps regulate vasoconstrictor signaling and blood pressure homeostasis (Heximer2003Hypertension; McNabb2020Emerging).

In the cardiovascular system, RGS2 inhibits Gq protein signaling, preventing prolonged activation of phospholipase C-β, which would otherwise lead to increased intracellular calcium levels and sustained contraction of vascular smooth muscle cells (Heximer2003Hypertension). This regulation is vital for normal blood pressure and vascular tone (Phan2017Human). RGS2 also interacts with certain isoforms of adenylate cyclase, modulating Gs-mediated signaling, which affects cAMP production and cellular responses (Roy2006RGS2).

RGS2 is involved in various physiological functions beyond cardiovascular regulation, including roles in the central nervous system, where it modulates neurotransmitter systems and affects mood and motor functions (McNabb2020Emerging). It also plays a role in suppressing inflammatory responses and airway constriction, highlighting its protective role in respiratory health (McNabb2020Emerging).

## Clinical Significance
Mutations and alterations in the RGS2 gene are associated with several diseases and conditions. In the central nervous system, RGS2 is linked to anxiety disorders, with specific single nucleotide polymorphisms (SNPs) such as rs4606 being notable risk factors for panic disorder and agoraphobia (McNabb2020Emerging). In Alzheimer's disease, reduced RGS2 expression correlates with increased sensitivity to amyloid-β treatment, suggesting a protective role against disease progression, although lower levels are also associated with better cognitive outcomes (McNabb2020Emerging; Hadar2016RGS2).

In cardiovascular health, RGS2 mutations and reduced expression are linked to hypertension. RGS2-deficient mice exhibit a hypertensive phenotype due to prolonged vasoconstrictor signaling, particularly involving angiotensin II (Heximer2003Hypertension). Human studies have identified RGS2 SNPs associated with hypertension, with mutations like Q2L leading to reduced protein expression (Phan2017Human; Phan2019LossofFunction).

In cancer, RGS2 expression levels are associated with tumor progression in certain subtypes, such as Mantle Cell Lymphoma and fibrolamellar carcinoma, although its exact role remains unclear (McNabb2020Emerging). In respiratory conditions, reduced RGS2 expression is observed in asthmatic patients, and its overexpression can mitigate airway hyperreactivity (McNabb2020Emerging).

## Interactions
RGS2 interacts with various proteins, influencing multiple signaling pathways. It binds to active Gαq subunits and M3 muscarinic acetylcholine receptors (M3Rs) at the plasma membrane. The interaction with Gαq subunits is stable, allowing RGS2 to act catalytically in two dimensions, while the interaction with M3Rs is more transient, suggesting different functional implications (Clark2007Active). RGS2 also interacts with adenylyl cyclase isoforms, specifically ACII and ACVI, as demonstrated by Bioluminescence Resonance Energy Transfer (BRET) experiments, indicating a specific interaction that may influence cellular signaling pathways (Roy2006RGS2).

In the context of protease-activated receptor 4 (PAR4)-mediated signaling, RGS2 forms complexes with PAR4 and Gαq, inhibiting downstream signaling events such as ERK phosphorylation and calcium mobilization. This interaction is dependent on the presence of Gαq, as other Gα subunits do not enhance the interaction between PAR4 and RGS2 (Kim2020Regulators). These interactions highlight the role of RGS2 in modulating GPCR signaling and its potential impact on physiological processes.


## References


[1. (McNabb2020Emerging) Harrison J. McNabb, Qian Zhang, and Benita Sjögren. Emerging roles for regulator of g protein signaling 2 in (patho)physiology. Molecular Pharmacology, 98(6):751–760, September 2020. URL: http://dx.doi.org/10.1124/molpharm.120.000111, doi:10.1124/molpharm.120.000111. This article has 14 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/molpharm.120.000111)

[2. (Clark2007Active) Michael A. Clark, Pooja R. Sethi, and Nevin A. Lambert. Active gαq subunits and m3 acetylcholine receptors promote distinct modes of association of rgs2 with the plasma membrane. FEBS Letters, 581(4):764–770, January 2007. URL: http://dx.doi.org/10.1016/j.febslet.2007.01.045, doi:10.1016/j.febslet.2007.01.045. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.febslet.2007.01.045)

[3. (AbramowNewerly2006RGS) Maria Abramow-Newerly, Anju A. Roy, Caroline Nunn, and Peter Chidiac. Rgs proteins have a signalling complex: interactions between rgs proteins and gpcrs, effectors, and auxiliary proteins. Cellular Signalling, 18(5):579–591, May 2006. URL: http://dx.doi.org/10.1016/J.CELLSIG.2005.08.010, doi:10.1016/j.cellsig.2005.08.010. This article has 300 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/J.CELLSIG.2005.08.010)

[4. (Kimple2009Structural) Adam J. Kimple, Meera Soundararajan, Stephanie Q. Hutsell, Annette K. Roos, Daniel J. Urban, Vincent Setola, Brenda R.S. Temple, Bryan L. Roth, Stefan Knapp, Francis S. Willard, and David P. Siderovski. Structural determinants of g-protein α subunit selectivity by regulator of g-protein signaling 2 (rgs2). Journal of Biological Chemistry, 284(29):19402–19411, July 2009. URL: http://dx.doi.org/10.1074/jbc.m109.024711, doi:10.1074/jbc.m109.024711. This article has 62 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m109.024711)

[5. (Kim2020Regulators) Yukeyoung Kim and Sungho Ghil. Regulators of g-protein signaling, rgs2 and rgs4, inhibit protease-activated receptor 4-mediated signaling by forming a complex with the receptor and gα in live cells. Cell Communication and Signaling, June 2020. URL: http://dx.doi.org/10.1186/s12964-020-00552-7, doi:10.1186/s12964-020-00552-7. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12964-020-00552-7)

[6. (Roy2006RGS2) Anju Anne Roy, Alessandra Baragli, Leah S. Bernstein, John R. Hepler, Terence E. Hébert, and Peter Chidiac. Rgs2 interacts with gs and adenylyl cyclase in living cells. Cellular Signalling, 18(3):336–348, March 2006. URL: http://dx.doi.org/10.1016/j.cellsig.2005.05.004, doi:10.1016/j.cellsig.2005.05.004. This article has 96 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2005.05.004)

[7. (Ross2000GTPaseActivating) Elliott M. Ross and Thomas M. Wilkie. Gtpase-activating proteins for heterotrimeric g proteins: regulators of g protein signaling (rgs) and rgs-like proteins. Annual Review of Biochemistry, 69(1):795–827, June 2000. URL: http://dx.doi.org/10.1146/annurev.biochem.69.1.795, doi:10.1146/annurev.biochem.69.1.795. This article has 940 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1146/annurev.biochem.69.1.795)

[8. (Phan2017Human) Hoa T.N. Phan, Benita Sjögren, and Richard R. Neubig. Human missense mutations in regulator of g protein signaling 2 affect the protein function through multiple mechanisms. Molecular Pharmacology, 92(4):451–458, August 2017. URL: http://dx.doi.org/10.1124/mol.117.109215, doi:10.1124/mol.117.109215. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/mol.117.109215)

[9. (Hadar2016RGS2) A Hadar, E Milanesi, A Squassina, P Niola, C Chillotti, M Pasmanik-Chor, O Yaron, P Martásek, M Rehavi, D Weissglas-Volkov, N Shomron, I Gozes, and D Gurwitz. Rgs2 expression predicts amyloid-β sensitivity, mci and alzheimer’s disease: genome-wide transcriptomic profiling and bioinformatics data mining. Translational Psychiatry, 6(10):e909–e909, October 2016. URL: http://dx.doi.org/10.1038/tp.2016.179, doi:10.1038/tp.2016.179. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/tp.2016.179)

[10. (Heximer2003Hypertension) Scott P. Heximer, Russell H. Knutsen, Xiaoguang Sun, Kevin M. Kaltenbronn, Man-Hee Rhee, Ning Peng, Antonio Oliveira-dos-Santos, Josef M. Penninger, Anthony J. Muslin, Thomas H. Steinberg, J. Michael Wyss, Robert P. Mecham, and Kendall J. Blumer. Hypertension and prolonged vasoconstrictor signaling in rgs2-deficient mice. Journal of Clinical Investigation, 111(4):445–452, February 2003. URL: http://dx.doi.org/10.1172/jci15598, doi:10.1172/jci15598. This article has 209 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci15598)

[11. (Tesmer2009Chapter) John J.G. Tesmer. Chapter 4 Structure and Function of Regulator of G Protein Signaling Homology Domains, pages 75–113. Elsevier, 2009. URL: http://dx.doi.org/10.1016/S1877-1173(09)86004-3, doi:10.1016/s1877-1173(09)86004-3. This article has 77 citations.](https://doi.org/10.1016/S1877-1173(09)86004-3)

[12. (Phan2019LossofFunction) Hoa T.N. Phan, William F. Jackson, Vincent S. Shaw, Stephanie W. Watts, and Richard R. Neubig. Loss-of-function mutations in human regulator of g protein signaling rgs2 differentially regulate pharmacological reactivity of resistance vasculature. Molecular Pharmacology, 96(6):826–834, October 2019. URL: http://dx.doi.org/10.1124/mol.119.116822, doi:10.1124/mol.119.116822. This article has 7 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/mol.119.116822)